AstraZeneca has secured $486m from the US Government for the development and supply of 100,000 doses of its potential AZD7442 antibody cocktail for the treatment of Covid-19.Under the current agreement, AstraZeneca (AZN) plans to supply up to 100,000 doses towards the end of 2020. In addition, the US government has an option to buy up to another 1 million doses in 2021.AZD7442, which is a combination of 2 long-acting antibodies (LAABs), will be evaluated in 2 Phase 3 clinical trials. The two AZD7442 trials, which will enroll over 6,000 adults testing the antibody cocktail for the prevention of Covid-19 at …read more
Source:: Yahoo Finance
